EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study)

Hani M Babiker iD, Matthew D Kay, Carol Stuehm, Gregory Woodhead, Phillip H Kuo

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Hani M Babiker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology-Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Blue Earth Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Suspicious F-18 fluciclovine PET/CT findings for osseous metastases from prostate cancer (PC) were targeted for core needle biopsy. We correlated the maximum standardized uptake value (SUVmax) of biopsied lesions, with biopsy results, other diagnostic outcomes, and blood and tissue molecular analysis (TMA). Material and Methods Patients with castrate resistant prostate cancer (CRPC) were recruited from a university oncology clinic. SUVmax, histology, blood, and TMA were correlated.

Results

Fifteen patients were enrolled and 12 underwent bone biopsies. Fifty percent of bone biopsies demonstrated malignancy. Higher SUVmax was associated with positive biopsies for adenocarcinoma (P = .003), and lesions with SUVmax ≥ 5.1 were all positive for malignancy. Significant correlation between blood and somatic TMA (P = .002) was also found.

Conclusion

Higher uptake of F-18 fluciclovine was associated with higher predictive value for osseous metastasis on biopsy. There was a significant correlation between blood and TMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBone NeoplasmsAdenocarcinomaMaleHumansPositron Emission Tomography Computed TomographyPilot ProjectsProstate

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology-Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida, Jacksonville, FL, USA.
  • Department of Medical Imaging, University of Arizona, Tucson, AZ, USA.
  • Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, AZ, USA.

ORCID-Profile: Hani M Babiker

Förderung

  • NCI NIH HHS
  • Blue Earth Diagnostics

Zitieren

APA

Babiker, H. M., Kay, M. D., Stuehm, C., Woodhead, G., & Kuo, P. H. (2023). A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study). The Oncologist. https://doi.org/10.1093/oncolo/oyad242

Vancouver

Babiker HM, Kay MD, Stuehm C, Woodhead G, Kuo PH. A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study). The Oncologist. 2023. doi:10.1093/oncolo/oyad242

BibTeX
@article{Babiker2023,
  author = {Babiker, Hani M and Kay, Matthew D and Stuehm, Carol and Woodhead, Gregory and Kuo, Phillip H},
  title = {A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study)},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad242}
}
Kostenlos starten →